Change search
ReferencesLink to record
Permanent link

Direct link
Residual Prostate Cancer in Patients Treated with Endocrine Therapy with or Without Radical Radiotherapy: A Side Study of the SPCG-7 Randomized Trial.
Umeå University, Faculty of Medicine, Department of Medical Biosciences, Pathology. (Anders Bergh)
Show others and affiliations
2011 (English)In: International journal of radiation oncology, biology, physics, ISSN 1879-355X, Vol. 80, no 1, 55-61 p.Article in journal (Refereed) Published
Abstract [en]

PURPOSE: The Scandinavian Prostate Cancer Group-7 randomized trial demonstrated a survival benefit of combined endocrine therapy and external-beam radiotherapy over endocrine therapy alone in patients with high-risk prostate cancer. In a subset of the study population, the incidence and clinical implications of residual prostate cancer in posttreatment prostate biopsy specimens was evaluated.

METHODS AND MATERIALS: Biopsy specimens were obtained from 120 of 875 men in the Scandinavian Prostate Cancer Group-7 study.

RESULTS: Biopsies were performed at median of 45 months follow-up. In 63 patients receiving endocrine treatment only and 57 patients receiving combined treatment, residual cancer was found in 66% (n = 41) and 22% (n = 12), respectively (p < 0.0001). The vast majority of residual tumors were poorly differentiated (Gleason score >/=8). Endocrine therapy alone was predictive of residual prostate cancer: odds ratio 7.49 (3.18-17.7), p < 0.0001. In patients with positive vs. negative biopsy the incidences of clinical events were as follows: biochemical recurrence 74% vs. 27% (p < 0.0001), local progression 26% vs. 4.7% (p = 0.002), distant recurrence 17% vs. 9.4% (p = 0.27), clinical recurrence 36% vs. 13% (p = 0.006), cancer-specific death 19% vs. 9.7% (p = 0.025). In multivariable analysis, biochemical recurrence was significantly associated with residual cancer: hazard ratio 2.69 (1.45-4.99), p = 0.002, and endocrine therapy alone hazard ratio 3.45 (1.80-6.62), p < 0.0001.

CONCLUSIONS: Radiotherapy combined with hormones improved local tumor control in comparison with endocrine therapy alone. Residual prostate cancer was significantly associated with serum prostate-specific antigen recurrence, local tumor progression, clinical recurrence, and cancer-specific death in univariable analysis. Residual cancer was predictive of prostate-specific antigen recurrence in multivariable analysis.

Place, publisher, year, edition, pages
Elsevier , 2011. Vol. 80, no 1, 55-61 p.
Keyword [en]
Prostate cancer, Radiotherapy, Endocrine therapy, Posttreatment biopsy, Outcome
National Category
Cancer and Oncology
Research subject
Medicine; Oncology
URN: urn:nbn:se:umu:diva-41776DOI: 10.1016/j.ijrobp.2010.01.072PubMedID: 20598453OAI: diva2:407763
Available from: 2011-04-01 Created: 2011-04-01 Last updated: 2011-06-17Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Bergh, AndersWidmark, Anders
By organisation
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 51 hits
ReferencesLink to record
Permanent link

Direct link